Smith D - Search Results

1

Phase II evaluations of cilengitide in asymptomatic patients with androgen-independent prostate cancer: scientific rationale and study design.

Beekman KW, Colevas AD, Cooney K, Dipaola R, Dunn RL, Gross M, Keller ET, Pienta KJ, Ryan CJ, Smith D, Hussain M. Beekman KW, et al. Among authors: smith d. Clin Genitourin Cancer. 2006 Mar;4(4):299-302. doi: 10.3816/CGC.2006.n.012. Clin Genitourin Cancer. 2006. PMID: 16729916

2

The use of prostate-specific antigen as a surrogate end point in the treatment of patients with hormone refractory prostate cancer.

Smith DC, Pienta KJ. Smith DC, et al. Urol Clin North Am. 1997 May;24(2):433-7. doi: 10.1016/s0094-0143(05)70390-6. Urol Clin North Am. 1997. PMID: 9126241

3

A phase II trial of oral estramustine and oral etoposide in hormone refractory prostate cancer.

Pienta KJ, Redman BG, Bandekar R, Strawderman M, Cease K, Esper PS, Naik H, Smith DC. Pienta KJ, et al. Among authors: smith dc. Urology. 1997 Sep;50(3):401-6; discussion 406-7. doi: 10.1016/S0090-4295(97)00228-8. Urology. 1997. PMID: 9301705 Clinical Trial.

4

Paclitaxel, estramustine, and etoposide in the treatment of hormone-refractory prostate cancer.

Pienta KJ, Smith DC. Pienta KJ, et al. Among authors: smith dc. Semin Oncol. 1997 Oct;24(5 Suppl 15):S15-72-S15-77. Semin Oncol. 1997. PMID: 9346227 Clinical Trial.

5

Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer.

Smith DC, Dunn RL, Strawderman MS, Pienta KJ. Smith DC, et al. J Clin Oncol. 1998 May;16(5):1835-43. doi: 10.1200/JCO.1998.16.5.1835. J Clin Oncol. 1998. PMID: 9586898 Clinical Trial.

6

Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma.

Redman BG, Smith DC, Flaherty L, Du W, Hussain M. Redman BG, et al. Among authors: smith dc. J Clin Oncol. 1998 May;16(5):1844-8. doi: 10.1200/JCO.1998.16.5.1844. J Clin Oncol. 1998. PMID: 9586899 Clinical Trial.

7

A phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate cancer.

Smith DC, Redman BG, Flaherty LE, Li L, Strawderman M, Pienta KJ. Smith DC, et al. Urology. 1998 Aug;52(2):257-60. doi: 10.1016/s0090-4295(98)00173-3. Urology. 1998. PMID: 9697791 Clinical Trial.

8

Quality-of-life evaluation in patients receiving treatment for advanced prostate cancer.

Esper P, Hampton JN, Smith DC, Pienta KJ. Esper P, et al. Among authors: smith dc. Oncol Nurs Forum. 1999 Jan-Feb;26(1):107-12. Oncol Nurs Forum. 1999. PMID: 9921573

9

Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer.

Sanda MG, Smith DC, Charles LG, Hwang C, Pienta KJ, Schlom J, Milenic D, Panicali D, Montie JE. Sanda MG, et al. Among authors: smith dc. Urology. 1999 Feb;53(2):260-6. doi: 10.1016/s0090-4295(98)00539-1. Urology. 1999. PMID: 9933036

10

Paclitaxel in the treatment of hormone-refractory prostate cancer.

Smith DC, Pienta KJ. Smith DC, et al. Semin Oncol. 1999 Feb;26(1 Suppl 2):109-11. Semin Oncol. 1999. PMID: 10190791 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

24,219 results

Search Page

Filters